Fundraising Fox

Intarcia Therapeutics

Boston, US · Delaware corporation · 4 known investors

Biopharmaceutical company developing innovative therapies for chronic diseases using proprietary drug delivery systems.

Biotech

Founders & leadership

JA
James AhlersExecutive
JY
John YeeExecutive
SZ
Sunita ZalaniExecutive
RT
Raymond T. KeaneExecutive
TA
Thomas AlessiExecutive
OH
Owen Hughes, Jr.Executive
PF
Paul FeldmanExecutive
AH
Anthony HurleyExecutive
KG
Kurt GravesExecutive
MB
Michelle BaronExecutive
DF
David FranklinExecutive

Board

BR
Bryan RobertsBoard director

Investors · 4

Bay City CapitalSan Rafael · $5M – $10M
Cycad Group LLCSanta Barbara
Foresite CapitalWest Hollywood
NXT VenturesMarblehead · $250K – $1M

Reported raises · per SEC filings

Form D private placements

$923.1M disclosed across 4 rounds · 2014–2019

▶$198.5MraisedJan 2020 · 45 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Kurt GravesExecutive Officer, Director
  • Bryan RobertsDirector
  • Gino SantiniDirector
  • Nancy ThornberryDirector
  • Patrick ConwayDirector
  • Jim RosenthalDirector
  • Anders VintherExecutive Officer
  • Bob KerreyDirector
  • David SpellmanExecutive Officer
  • Raymond KeaneExecutive Officer
  • Fred FiedorekExecutive Officer
  • Thane WettigExecutive Officer
  • Paul FeldmanExecutive Officer
  • Jay SkylerDirector
Offering amount
$280M
Amount sold
$198.5M
Sales commissions
$3M
Placement agents
Morgan Stanley & Co. LLC
First sale
Feb 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$524.6MraisedAug 2017 · 90 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Thomas AlessiExecutive Officer
  • James AhlersExecutive Officer
  • Raymond KeaneExecutive Officer
  • Glen SatoDirector
  • John YeeExecutive Officer
  • Bryan RobertsDirector
  • Emad RizkDirector
  • Kurt GravesExecutive Officer, Director
  • Michelle BaronExecutive Officer
  • Anthony HurleyExecutive Officer
  • Gino SantiniDirector
  • Jay SmithExecutive Officer
  • Nancy ThornberryDirector
  • Owen Hughes, Jr.Executive Officer
  • Sunita ZalaniExecutive Officer
  • Paul FeldmanExecutive Officer
  • Irwin ScherDirector
Offering amount
$850M
Amount sold
$524.6M
Sales commissions
$15.9M
Finders' fees
$218K
Placement agents
Raptor International, LLC, UBS Securities LLC, Morgan Stanley & Co. LLC
First sale
Sep 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.6KraisedJan 2017 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • James AhlersExecutive Officer
  • Irwin ScherDirector
  • John YeeExecutive Officer
  • Sunita ZalaniExecutive Officer
  • Raymond T. KeaneExecutive Officer
  • Emad RizkDirector
  • Thomas AlessiExecutive Officer
  • Glen SatoDirector
  • Owen Hughes, Jr.Executive Officer
  • Paul FeldmanExecutive Officer
  • Nancy ThornberryDirector
  • Anthony HurleyExecutive Officer
  • Michelle BaronExecutive Officer
  • Bryan RobertsDirector
  • Gino SantiniDirector
  • Kurt GravesExecutive Officer, Director
  • Jay SmithExecutive Officer
Offering amount
$3.6K
Amount sold
$3.6K
First sale
Dec 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$200MraisedApr 2014 · 38 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Kurt GravesExecutive Officer, Director
  • Gino SantiniDirector
  • Irwin ScherDirector
  • Glen SatoDirector
  • Michelle BaronExecutive Officer
  • Raymond T. KeaneExecutive Officer
  • Nancy ThornberryDirector
  • James AhlersExecutive Officer
  • Thomas AlessiExecutive Officer
  • David FranklinExecutive Officer
  • Bryan RobertsDirector
  • Owen Hughes, Jr.Executive Officer
  • Jay SmithExecutive Officer
Offering amount
$200M
Amount sold
$200M
Minimum investment
$14.4K
First sale
Mar 2014
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Intarcia’s diabetes drug-device combo voted down again by FDA panel | MedTech Divemedtechdive.com · Sep 2023Intarcia Therapeutics raises novel $225 million to develop exenatide pump – Drug R&D Insightyixiblog.wordpress.com · Apr 2015Intarcia Therapeutics Closes Novel $225 Million Synthetic Royalty Financing With Equity Conversion Option At $5.5 Billion Valuationprnewswire.com · Apr 2015Intarcia Therapeutics Secures Landmark $210-Million Financingdrug-dev.com · Nov 2012Intarcia raises $210M for PhIII, once-yearly diabetes drug | Fierce Biotechfiercebiotech.com · Nov 2012Intarcia Therapeutics, Inc. Raises $50 Million in a Series BB Financing - BioSpacebiospace.com · Mar 2007

Frequently asked questions

What does Intarcia Therapeutics do?
Biopharmaceutical company developing innovative therapies for chronic diseases using proprietary drug delivery systems.
Who are Intarcia Therapeutics's investors?
Intarcia Therapeutics's investors include Bay City Capital, Cycad Group LLC, Foresite Capital, NXT Ventures.
How much funding has Intarcia Therapeutics raised?
Intarcia Therapeutics has disclosed $923.1M raised across 4 rounds.
Where is Intarcia Therapeutics headquartered?
Intarcia Therapeutics is headquartered in Boston, US.